Abstract 532P
Background
Immune checkpoint inhibitors (ICIs) have come to be used for the treatment of the patients with malignant pleural mesothelioma (MPM). Although modified RECIST (mRECIST) criteria is the standard method to evaluate the antitumor efficacy of ICIs, it is sometimes difficult to distinguish progressive disease from pseudoprogression (PsPD). While serum soluble mesothelin related peptide (SMRP) is commonly known as a specific tumor marker of MPM, the significance of SMRP levels in determining the efficacy of ICI treatment has not been established.
Methods
We investigated the relationship between changes of serum SMRP levels and treatment response in MPM patients treated with ipilimumab plus nivolumab combination therapy at our hospital between June 2021 and January 2023.
Results
Twenty-eight patients were included in the study. Median age was 75 years (59-85). The number of histological subtypes of epithelioid, sarcomatoid, biphasic and desmoplastic were 18, 6, 3 and 1, respectively. Treatment response was evaluated by mRECIST. The number of patients who achieved partial response (PR), stable disease (SD) and progressive disease (PD) were 9, 16 and 3, respectively. Among 25 patients with PR and SD, PsPD was observed in 5 patients (PR/SD: 3/2). The median serum SMRP before treatment in all patients was 0.90 nmol/L (0.4 - 16.9)., and the change from baseline at the time of first evaluation was +0.1 nmol/L (-4.5 - +24.5), The median change of serum SMRP level from baseline in patients with PR, SD, PsPD and PD was 0.0 nmol/L (-1.0 - +1.4), +0.1 nmol/L (-4.5 - +4.5), +0.2 nmol/L (-0.9 - +0.9) and +19.5 nmol/L (+0.1 - +24.5), respectively. These results indicated that serum SMRP level in patients with PD already tended to increase at the time of first evaluation.
Conclusions
Our results suggested that changes in serum SMRP levels was useful in determining the efficacy of ICI treatment. We are planning to accumulate more cases in the future for further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract